$38.83
0.44% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US8688731004
Symbol
SRDX

Surmodics Inc Stock price

$38.83
-2.42 5.87% 1M
+9.04 30.35% 6M
+2.48 6.82% YTD
+0.71 1.86% 1Y
-21.49 35.63% 3Y
-7.33 15.88% 5Y
+19.12 97.01% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.17 0.44%
ISIN
US8688731004
Symbol
SRDX
Sector

Key metrics

Market capitalization $553.99m
Enterprise Value $549.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.55
P/S ratio (TTM) P/S ratio 4.59
P/B ratio (TTM) P/B ratio 4.69
Revenue growth (TTM) Revenue growth -7.49%
Revenue (TTM) Revenue $120.82m
EBIT (operating result TTM) EBIT $-7.48m
Free Cash Flow (TTM) Free Cash Flow $-5.86m
Cash position $38.18m
EPS (TTM) EPS $-0.10
P/E forward negative
P/S forward 4.50
EV/Sales forward 4.46
Short interest 4.37%
Show more

Is Surmodics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Surmodics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Surmodics Inc forecast:

3x Hold
100%

Analyst Opinions

3 Analysts have issued a Surmodics Inc forecast:

Hold
100%

Financial data from Surmodics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
121 121
7% 7%
100%
- Direct Costs 35 35
29% 29%
29%
86 86
17% 17%
71%
- Selling and Administrative Expenses 46 46
5% 5%
38%
- Research and Development Expense 38 38
22% 22%
32%
1.58 1.58
85% 85%
1%
- Depreciation and Amortization 9.06 9.06
2% 2%
7%
EBIT (Operating Income) EBIT -7.48 -7.48
619% 619%
-6%
Net Profit -1.40 -1.40
94% 94%
-1%

In millions USD.

Don't miss a Thing! We will send you all news about Surmodics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Surmodics Inc Stock News

Neutral
Business Wire
3 months ago
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has been awarded a group purchasing agreement for thrombectomy products with Premier, Inc. Effective June 1, 2024, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-nego...
Neutral
Accesswire
3 months ago
NEW ORLEANS, LA / ACCESSWIRE / May 30, 2024 / Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Neutral
PRNewsWire
3 months ago
NEW YORK , May 29, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Surmodics, Inc. (NASDAQ: SRDX) and its board of directors concerning the proposed acquisition of the company by GTCR. Stockholders will receive $43.00 for each share of Surmodics stock that they hold.
More Surmodics Inc News

Company Profile

SurModics, Inc. engages in the provision of medical device and in vitro diagnostic technologies to the healthcare industry. It operates through the Medical Device and In Vitro Diagnostics segments. The Medical Device segment designs, develops, and manufactures interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment consists of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.

Head office United States
CEO Gary Maharaj
Employees 376
Founded 1979
Website www.surmodics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today